TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05481515

Intervention type: DEVICE
Intervention: Pulse oximetry
Description: Pulse oximeters will be evaluated against routine arterial blood gas measurements

Intervention type: DEVICE
Intervention: Spectrophotometry
Description: Spectrophotometry will be used to measure skin tone
Study: NCT06087783

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental product - Fortifit® Powder
Description: Two servings (40 grams each) of powder (Fortifit®; Nutricia) which has to be dissolved in 125 ml of water. Per serving, 20 g whey protein, 3 g total leucine, 9 g carbohydrates, 3 g fat, 800 IU vitamin D, and a mixture of vitamins, minerals, and fibers.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care
Description: Control group receiving no nutritional intervention or on-demand non muscle-targeted intervention such as nutritional counseling with or without oral nutritional supplement
Study: NCT05047679

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Perioperative Pain Neuroscience Education
Description: Perioperative pain neuroscience education addresses modifiable preoperative risk factors, and in particular cognitive and emotional risk factors, such as fear of movement and pain catastrophizing (i.e., excessively negative orientation toward pain). This education is a cognitive-based therapeutic intervention which reconceptualizes pain, informs patients about what to expect from the evolution of their pain, de-emphasizes the patho-anatomical content and focuses on factors contributing to the development of pain. It explains this all within a biopsychosocial framework, which means that it aims to optimize patients' beliefs. Furthermore, it intends to reassure the patient about the decision to have surgery, to potentially decrease perioperative distress.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Perioperative Biomedical Education
Description: Perioperative biomedical education will discuss the anatomy, physiology and biomechanics of the lumbar spine with the patient. Additionally, the content of this education includes the expected course of postoperative back and leg pain, as well as ergonomic advice on patient-specific daily activities. This education will be given within a biomedical framework, which means that it aims to explain the patients' complaints and recovery while focusing on anatomy and biomechanics, as opposed to patients' beliefs and cognitions.
Study: NCT06500104

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Glucose powder
Study: NCT06069687

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MELPIDA
Description: A single intrathecal infusion of 10 mL at 1E14 vg/mL for a total dose of 1E15 vg
Study: NCT04848727

Intervention type: OTHER
Intervention: Detecting asymmetric lung disease like atelectasis or pneumothorax with electrical impedance tomography (EIT)
Description: The EIT system will be placed at the subject's bedside to collect EIT measurements: Ventilation distribution%, changes in regional aeration in arbitrary units (AU), dependent and non-dependent silent spaces. A data acquisition cart will also be placed at the subject's bedside to collect hemodynamic and respiratory parameters measurements including: Heart rate (HR), blood pressure (BP), respiratory rate (RR), fraction of inspired oxygen (FiO2), transcutaneous carbon dioxide (TcCO2), and peripheral oxygen saturation (SpO2) via bedside monitoring devices.~The LuMon belts for neonates are disposable single-patient use belts that are adhesive-free. EIT measurements and data will be collected on each timeperiods (t1 and t2) for approximately 15-30 minutes on invasive or non-invasive ventilatory support.
Study: NCT05876637

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Left Nostril Breathing
Description: The participants which will show cardiovascular hyper reactivity towards CPT will be divided into 2 groups having 30 participants in each group. Experimental group will receive Left Nostril Breathing(slow, deep breath taken through your left nostril while closing your right nostril with your right thumb. Then just as gently exhale long, slowly, and completely through the left nostril, just as gently. It will be done while sitting) for 10 minutes twice a day for the duration of 12 weeks. Follow up will be taken through administration Cold pressor test after every 4,8 and 12 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional
Description: 30 participants will be recruited in conventional group which will receive simple deep breathing exercises of 3 sessions per week for the duration of 12 weeks.Follow up will be taken after every 4,8 and 12 weeks.
Study: NCT04936165

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low-Level Laser Therapy
Description: Use 810-nm-photosource to irradiate the participants' brain and forearm for 10 minutes with a water-cooling radiator to keep it at 25 ± 0.5 ℃.
Study: NCT05800158

Intervention type: DIAGNOSTIC_TEST
Intervention: Applied Biosystems™ TaqPath™ COVID-19 Diagnostic PCR Kit
Description: A reverse transcription, real-time polymerase chain reaction (RT-qPCR) test for the qualitative detection of SARS-CoV-2.
Study: NCT06142318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Description: Dose climbing started two weeks before the start of radiotherapy, and the maintenance dose of 600mg bid was reached in the third week until the end of radiotherapy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dose climbing started two weeks before the start of radiotherapy, and the maintenance dose of 600mg bid was reached in the third week until the end of radiotherapy.
Study: NCT05438875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: all-trans retinoic acid
Description: ATRA 10 mg, 2 times a day, orally.The treatment course is 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: The initial dose of eltrombopag is 50 mg/time, once a day, and the dose is increased when the platelet count is lower than 5×109/L, the maximum is 75 mg/d, and the dose is higher than 200×109/L. When the drug is temporarily discontinued, the drug is re-administered according to the platelet count.The treatment course is 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eltrombopag
Description: The initial dose of eltrombopag is 50 mg/time, once a day, and the dose is increased when the platelet count is lower than 5×109/L, the maximum is 75 mg/d, and the dose is higher than 200×109/L. When the drug is temporarily discontinued, the drug is re-administered according to the platelet count.The treatment course is 12 weeks.
Study: NCT05260437

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV2CoV (2 µg)
Description: Study vaccine was administered as a single intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV2CoV (4 µg)
Description: Study vaccine was administered as a single intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV2CoV (8 µg)
Description: Study vaccine was administered as a single intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV2CoV (12 µg)
Description: Study vaccine was administered as a single intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV2CoV (16 µg)
Description: Study vaccine was administered as a single intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV2CoV (20 µg)
Description: Study vaccine was planned to be administered intramuscularly. No vaccine was administered in the CV2CoV (20 µg) Group, since there were no participants enrolled in it.
Study: NCT05676515

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: culture media
Description: spliting of biological material and use of three culture media

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: culture media
Description: spliting of biological material and use of three culture media

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: culture media
Description: spliting of biological material and use of three culture media
Study: NCT06146933

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Glucometer Test
Description: blood glucose measurement using finger tip capillary blood using BGM

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Refernce Measurement
Description: blood glucose measurement using finger tip capillary blood using reference method
Study: NCT05966324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: baxdrostat
Description: Baxdrostat is an aldosterone synthase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: baxdrostat
Description: Baxdrostat is an aldosterone synthase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: baxdrostat
Description: Baxdrostat is an aldosterone synthase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: baxdrostat
Description: Baxdrostat is an aldosterone synthase inhibitor
Study: NCT05405192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dostarlimab
Description: First four cycles of Dostarlimab will be given intravenously (IV) on day 1 of each of the 21-day cycle at a dose of 500 milligrams (mg). The next 16 cycles of Dostarlimab will be given on day 1 of each of the 42-day cycles at a dose of 1,000 mg.
Study: NCT05175690

Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnostic Software as Medical Device
Description: AudibleHealth Dx is an investigational Dx SaMD consisting of an ensemble of software subroutines that interacts with a proprietary database of signal data signatures (SDS) using Artificial Intelligence/Machine Learning (AI/ML) to analyze forced cough vocalization signal data signatures (FCV-SDS) for diagnostic purposes. The intended use for the AudibleHealth Dx AI/ML-based Dx SaMD using FCV-SDS is for the diagnosis of acute and chronic illnesses.~The AudibleHealth Dx is a cloud-based AI/ML (locked ML) diagnostic software as medical device (Dx SaMD) with a mobile app based graphical user interface (GUI) designed to operate with COTS Android Operating System (OS) and Apple OS based mobile devices. The AudibleHealth Dx system uses a forced cough vocalization (FCV) signal data signature (SDS) to diagnose COVID-19 illness in ambulatory adults. Results are sent to ordering physicians, State Health Departments, and participants using Health Level 7 (HL7) compliant communication protocols.
Study: NCT05376696

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Set For Variability
Description: This intervention will focus on training students to use a sound variation of grapheme correspondence rule in order to read an irregular spelling word correctly.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Current Best Practices
Description: This active control intervention will focus on training students to use grapheme-phoneme correspondence rules and sight words in the absence of set-for-variability component
Study: NCT06321796

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: MTP-101P
Description: MTP-101P is comprised of standardized dose of total fecal microbiota purified from the stool of healthy donors. Donors are carefully screened via health status questionnaires, physical examinations, reviews of comprehensive medical history, clinical laboratory evaluations, serologic and genomic tests for infectious diseases and metabolic health, and stool-related pathogen testing. The material from the donors is purified to remove the majority of non-bacterial material, washed, lyophilized, and provided to the patient in a sachet contained within a mixing bottle.~Duration: 12.5 Weeks

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: Oral vancomycin is an antibiotic used for treating C. difficile-associated diarrhea and staphylococcal-induced enterocolitis.~Duration: 10 Days

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Magnesium Citrate
Description: Magnesium citrate is a common over-the-counter laxative and bowel cleanse.~Duration: 1 Day

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Magnesium Citrate
Description: Magnesium citrate is a common over-the-counter laxative and bowel cleanse.~Duration: 1 Day

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Antacid
Description: The antacid will be aluminum/magnesium hydroxide, 1x/day, 5 minutes before the MTP-101P. Each 5 ml consists of Aluminum Hydroxide - 200 mg, Magnesium Hydroxide - 200 mg, and Simethicone - 20 mg. If some participants cannot tolerate the aluminum/magnesium hydroxide, we will allow calcium carbonate alternatives equivalent in acid neutralizing capacity.~Duration: 12.5 weeks

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Antacid
Description: The antacid will be aluminum/magnesium hydroxide, 1x/day, 5 minutes before the MTP-101P. Each 5 ml consists of Aluminum Hydroxide - 200 mg, Magnesium Hydroxide - 200 mg, and Simethicone - 20 mg. If some participants cannot tolerate the aluminum/magnesium hydroxide, we will allow calcium carbonate alternatives equivalent in acid neutralizing capacity.~Duration: 12.5 weeks

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo MTP-101P
Description: The same packaging will be used as for MTP-101P, but the sachets will contain a freeze-dried mixture of normal saline containing 10% Trehalose.~Duration: 12.5 weeks

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vancomycin
Description: Same packaging and liquid carrier and flavoring used as for the oral vancomycin, but no vancomycin.~Duration: 10 days
Study: NCT06144333

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: RIPH2
Description: * Blood sampling by capillary~* Swab sampling~* Blood sampling by venous punction~* Salivary sample, sputum, expectoration:
Study: NCT05307432

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SPI+ Delivered by ED Staff
Description: ED staff will deliver SPI+ (Safety Planning Intervention plus follow-up phone calls) to patients at risk for suicide in the ED who are not admitted to an inpatient unit.
Study: NCT06399094

Intervention type: OTHER
Intervention: Lung sound recordings
Description: The lung sound recordings will be made during a consultation scheduled as part of the patient's usual follow-up, after obtaining the patient's non-opposition.

Intervention type: OTHER
Intervention: Lung sound recordings
Description: The lung sound recordings will be made during a consultation scheduled as part of the patient's usual follow-up, after obtaining the patient's non-opposition.
Study: NCT04804943

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NOA-001
Description: NOA-001 will be replaced regularly (at 22 to 24 hours after the initiation of procedure), and will be continuously performed until 168 hours from the enrollment.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NOA-001
Description: NOA-001 will be replaced regularly (at 22 to 24 hours after the initiation of procedure), and will be continuously performed until 168 hours from the enrollment.
Study: NCT05307432

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SPI+ Delivered by SPCC Clinicians
Description: The Suicide Prevention Consultation Center (SPCC) will be located external to the Emergency Department (ED). ED staff will be able to refer patients at risk for suicide to the SPCC. Licensed and credentialed mental health clinicians will deliver SPI+ (Safety Planning Intervention plus follow-up phone calls) via telehealth to patients at risk for suicide in the ED who are not admitted to an inpatient unit.
Study: NCT06416293

Intervention type: OTHER
Intervention: Questionnaire patients
Description: Completion of a two-part questionnaire with a special focus on communication around the breast cancer diagnosis. Tumor stage and therapies received are also surveyed. The questionnaire can be answered online via a secure tool (REDCap) or in paper form.

Intervention type: OTHER
Intervention: Questionnaire physicians
Description: Completion of a questionnaire with a special focus on communication around the breast cancer diagnosis
Study: NCT05505526

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Description: BL33 is located in the third posterior sacral foramen; BL35, 0.5 cun (≈10mm) lateral to the extremity of the coccyx; and SP6 posterior to the medial border of the tibia, 3 cun superior to the prominence of the medial malleolus. BL33 will be inserted by needles of 0.30×75mm size at the angle of 45°, inward and downward, till the depth of 60-70mm. BL35 will be inserted by needles of 0.30×75mm size, slightly outward and upward, till the depth of 60-70mm. SP6 will be inserted by needles of 0.30×40mm till the depth of 25-30mm. All the needles will be lifted, thrust and twisted evenly for three times, right after insertion, to induce the sensation of deqi. Electronic acupuncture apparatus (Yingdi KWD 808 I electro pulse acupuncture therapeutic apparatus, Changzhou Yingdi Electronic Medical Device Co., Ltd) will be connected to the three pairs of needles transversally, with continuous wave of 20 Hertz (Hz), electric current of 2-6.5 milliampere (mA) for BL33 and BL35, and 1mA-3.5mA for SP6.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham electroacupuncture
Description: Sham BL33 is in the area of 1 cun (≈20mm) horizontally outside BL33; sham BL35, 1 cun (≈20mm) horizontally outside BL35; Sham SP6, in the middle of SP6 and tendons. The three pairs of acupoints will be inserted by needles of 0.30×40mm size to a depth of 2-3mm till the needles can stand still. No manipulations will be conducted, and the sensation of deqi will not be induced. Electronic acupuncture apparatus (Yingdi KWD 808 I electro pulse acupuncture therapeutic apparatus, Changzhou Yingdi Electronic Medical Device Co., Ltd) will be connected to the three pairs of needles transversally, with continuous wave of 20Hz and minimal electric current (ideally at a degree which participant can just percept). In about 30 seconds, the electric current will be turned down, leaving the indicator light and ticking sound on.
Study: NCT05302622

Intervention type: OTHER
Group type: OTHER
Intervention: There is no intervention planning
Description: There is no intervention planning

Intervention type: OTHER
Group type: OTHER
Intervention: There is no intervention planning
Description: There is no intervention planning

Intervention type: OTHER
Group type: OTHER
Intervention: There is no intervention planning
Description: There is no intervention planning
Study: NCT05428813

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: art therapy techniques
Description: Art therapy is a method that allows individuals to increase their self-awareness and realize their emotions better through artistic techniques.
Study: NCT06399939

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nap
Description: Naps are common but promoted by soothing, lying the infant down, and/or rocking and massaging

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wake
Description: Wake is encouraged by keeping the infant upright, providing stimulation (e.g., reading books, handing toys)
Study: NCT06469931

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: range of motion exercises
Description: In addition to range of motion exercises for wrist and hand and splinting, 3 sessions of ozone therapy will be applied once a week.
Study: NCT06399094

Intervention type: OTHER
Intervention: Lung sound recordings
Description: The lung sound recordings will be made during a consultation scheduled as part of the patient's usual follow-up, after obtaining the patient's non-opposition.
Study: NCT06038162

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Parallel connection
Description: The RRT machine is connected on a separate vascular access (dialysis catheter).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Integrated connection
Description: A connection of the RRT machine with the input and output lines directly on the ECMO circuit.
Study: NCT05029219

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arm I (Virtual reality group)
Description: In the preparatory session, the participant is given a survey. It is about demographic information such as gender, age, and age, as well as prior experience with the procedure. The primary test is performed with a fluoroscopy guided lumbar transforaminal epidural block with a human-shaped phantom.~After that, the test group and the control group receive the same audiovisual education for about 5 minutes. The test group receives about 60 minutes of training using a virtual reality program.
Study: NCT06469931

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: range of motion exercises
Description: In addition to range of motion exercises for wrist and hand and splinting, 3 sessions of ozone therapy will be applied once a week.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy
Description: Patients in this group will receive ESWT once a week for 3 consecutive weeks in addition to range of motion exercises for wrist and hand and splinting.
Study: NCT04915209

Intervention type: OTHER
Group type: OTHER
Intervention: Narrative interviews
Description: During the workshop, the participants will collectively create a common representation of the patient journey and co-design the envisioning care delivery model that support both social care and medical care.
Study: NCT06469931

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ozone therapy
Description: ozone therapy
Study: NCT05029219

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Arm II (Self study group)
Description: In the preparatory session, the participant is given a survey. It is about demographic information such as gender, age, and age, as well as prior experience with the procedure. The primary test is performed with a fluoroscopy guided lumbar transforaminal epidural block with a human-shaped phantom.~After that, the test group and the control group receive the same audiovisual education for about 5 minutes. The control group have provided with video materials and books provided during audiovisual education and have given time for self-study for 60 minutes. Subsequently, a second test is performed with a fluroscopy-guided lumbar transforaminal epidural block with a human-shaped phantom.
Study: NCT05584748

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulation
Description: tDCS is planned to be administered via electrodes positioned over the left dlPFC (anodal/sham electrode) and the left supraorbital area (reference electrode).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: tDCS is planned to be administered via electrodes positioned over the left dlPFC (anodal/sham electrode) and the left supraorbital area (reference electrode).